Funding for this research was provided by:
UC | UCLA | Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles
California Institute for Regenerative Medicine
Cancer Research Institute
Mark Foundation for Cancer Research Jean and Stephen Kaplan
U.S. Department of Health & Human Services | National Institutes of Health (RO1NS117912, P50AR052646)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Defense
Coalition to Cure Calpain 3
Article History
Received: 1 December 2022
Revised: 20 January 2023
Accepted: 7 February 2023
First Online: 8 November 2023
Competing interests
: DBK is a Scientific Advisory Board member for Allogene Therapeutics, ImmunoVec, Pluto Therapeutics, MyoGene Bio, Innoskel, and an ad hoc consultant for Cimeio Therapeutics, TransformaTx, and bluebird bio. YYC is a founder of, holds equity in, and received consulting fees from ImmPACT Bio. She is a member of the Scientific Advisory Board of, and holds equity in Catamaran Bio, Notch Therapeutics, Pluto Immunotherapeutics, Prime Medicine, Sonoma Biotherapeutics, and Waypoint Bio. MJS is a founder of and holds equity in MyoGene Bio and SkyGene Bio.